How Pancreatic Cancer Is Treated

Treatments for pancreatic cancer include surgery, chemotherapy, targeted therapy, and clinical trials focused on newer treatments, such as immunotherapy.

Treatment options currently available can be classified as:

  • Curative: These treatments are done with the hope of achieving long-term survival with the disease.
  • Palliative: These treatments that may not extend survival, but improve quality of life for those living with the disease.

Treatments that address cancer itself can be further categorized as:

  • Local treatments: These are treatments that treat cancer where it originated, and include surgery and radiation therapy.
  • Systemic treatments: These treatments are designed to address cancer cells anywhere in the body (including metastases) and include chemotherapy and some of the newer medications available in clinical trials.

Here, an overview of the options currently available for treatment of both early and advanced pancreatic cancers.

Types of Pancreatic Cancer
Verywell / Alexandra Gordon


Surgery is the only treatment option that could result in curing pancreatic cancer. If successful, such a procedure would remove all the cancer cells. Doing so may at least increase the chances of long-term survival.

Only 15% to 20% of people with pancreatic cancer are candidates for surgery.

Unfortunately, it can be difficult, even with the imaging tests we have available, to know whether cancer has spread to the point where surgery is inadvisable before the surgery itself is done. (Treating pancreatic cancers that have spread, including stage 3 and stage 4 tumors, does not increase survival but does significantly lessen the quality of life. ) During surgery, doctors discover that cancer has spread too far for the procedure to be considered a good option roughly 20% of the time.

Some physicians recommend doing a laparoscopic biopsy (a test in which several small incisions are placed in the abdomen and a probe is placed in order to remove a small piece of the pancreas and explore the surrounding area) before surgery is considered. Doing so may reduce the chance of unnecessary surgery and the subsequent pain and complications of it.

Challenges and Considerations

The pancreas lies just behind the stomach and is next to several vital structures. Directly behind the pancreas is a collection of major blood vessels. If a tumor is described as "locally advanced," it means that the tumor may be enveloping these major blood vessels, making the removal of all the tumor without damaging the vessels almost impossible. When this happens, a person may or may not be a candidate for surgery. Certain high-volume centers are potentially able to remove and reconstruct blood vessels to varying degrees - so in these cases cancers that were previously thought to be inoperable are now potentially operable. 

Understanding anatomy is also helpful for those who learn they have borderline resectable disease. This includes people who have cancer that envelopes 50% or less of a blood vessel. There is no standard treatment for this situation, but some physicians believe that giving chemotherapy (with or without radiation therapy) to shrink the tumor might do so enough that it can be removed surgically.


If you are considered a candidate for surgery, the following options may be performed:

  • Whipple procedure (pancreaticoduodenectomy): The Whipple procedure is the most common procedure done for pancreatic cancer and is an option for people who have early-stage cancer of the head of the pancreas. In this surgery the gallbladder, common bile duct, a large part of the pancreas (including the head), part of the duodenum, part of the stomach, the spleen, and nearby lymph nodes are removed. Part of the body and the tail of the pancreas are left behind in order to preserve its function (the production of digestive enzymes and hormones).
  • Whipple procedure variations: There are several variations on the classic Whipple procedure that preserve more of the stomach and first part of the small intestine, most commonly known as pylorus-preserving pancreaticoduodenectomy. These procedures are done to help minimize certain postoperative complications. 
  • Distal pancreatectomy: Cancers in the body or tail of the pancreas are seldom operable, but when they are, the tail of the pancreas may be removed with or without the spleen.
  • Total Ppancreatectomy: Total pancreatectomy is essentially the same as a Whipple procedure, but differs in that the entire pancreas is removed. This is done when it's necessary to remove all the visible tumor.

Side Effects and Complications

All of the surgical options for pancreatic cancer are very major surgeries, and complications or death are not uncommon. Common risks include the risks associated with general anesthesia, bleeding, infections, and the development of blood clots after surgery.

The risk of blood clots is very high in people with pancreatic cancer, and surgery adds to this risk. Using compression devices on the legs during and after surgery, as well as blood thinners can reduce this to some degree.

The most common long-term complication of surgery is a recurrence of cancer, and this is, unfortunately, far too common. The chance that pancreatic cancer will recur after surgery depends on many factors, and only your surgeon will be able to estimate what this may mean for you. 

Each procedure can also result in other issues. For example, in pylorus-preserving pancreaticoduodenectomy, removal of part of the stomach and the first part of the small intestine can result in dumping syndrome, a condition that can cause significant diarrhea shortly after eating. It can also increase the chance of bile reflux, a condition where the bile goes the wrong direction and enters the stomach resulting in inflammation and discomfort.

When total pancreatectomy is performed, all pancreatic function is, of course, completely lost. There is no production of insulin, glucagon, or digestive enzymes. Diabetes is inevitable and insulin therapy and enzyme replacement are necessary following surgery.

Whether you will need supplemental enzymes or hormones after part of the pancreas is removed depends on several factors, including the amount of damage to the pancreas from the tumor prior to surgery. Fortunately, people do not need their entire pancreas to make an adequate amount of insulin, and living a normal life is possible after surgery.

Palliative Surgery

Surgery may also be done for people with pancreatic cancer to reduce symptoms but not cure the disease. It's very common for the common bile duct to be blocked by these tumors. When this occurs, a stent may be placed via endoscopy or surgery to bypass the duct may be done.

Choosing a Hospital

If you are a candidate for surgery, it is extremely important that you seek care at a hospital that does a large volume of these surgeries. That means choosing a facility that performs more than 15 pancreatic cancer surgeries each year and can report a lower risk of death and a shorter hospital stay.

Pancreatic Cancer Doctor Discussion Guide

Get our printable guide for your next doctor's appointment to help you ask the right questions.

Doctor Discussion Guide Woman


Chemotherapy may be used in a few ways for people with pancreatic cancer.

Neoadjuvant chemotherapy: Neoadjuvant chemotherapy refers to the use of chemotherapy before surgery in order to shrink a tumor so that surgery is possible (as discussed above).

Adjuvant chemotherapy: Adjuvant chemotherapy refers to chemotherapy that is used in addition to surgery. Pancreatic cancers commonly recur following surgery, meaning that cancer cells are often left behind (but may be too small to be seen on imaging tests). When chemotherapy is used after surgery, it's thought to improve survival by three to four months.

Palliative chemotherapy: Most of the time when chemotherapy is considered for pancreatic cancer, it is given with the hopes that it will extend life, but not cure cancer. Overall, chemotherapy results in small, but significant improvements in length of survival. 

Drugs most commonly used include:

  • Abraxane (albumin-bound paclitaxel)
  • Gemzar (gemcitabine)
  • 5-FU (fluorouracil)
  • Onivyac (irinotecan liposome injection)

These drugs are usually given in combination and may be given along with targeted therapy, immunotherapy, or sometimes, radiation therapy. The drugs are given intravenously at certain intervals (such as once a week for three weeks, followed by one week off) for a number of cycles.

A three-drug combination, Folfirinex (5-FU/leucovorin, irinotecan, and oxaliplatin) appears to work quite well, but is more toxic than other options and is used primarily for people in good general health (those who have a good performance status).

2018 review of studies looking at various combinations of drugs found that Folfirinex had the greatest effect on lengthening survival.

Side Effects of Chemotherapy

The side effects of chemotherapy can be significant and include hair loss; nausea and vomiting (though treatments to reduce these symptoms have improved tremendously in recent years); bone marrow suppression resulting in lowered counts of white bloods, red blood cells (anemia), and platelets, and more.

Targeted Therapy

Targeted therapies are drugs that target specific pathways in the growth of cancer cells. Since these treatments are aimed specifically at cancer cells they often (but not always) have fewer side effects than chemotherapy.

An oral drug that is sometimes used for people with pancreatic cancer, Tarceva (erlotinib) works by blocking a path in the growth of the cancer cells. Rather than killing the cancer cells, it essentially starves them and stops their replication. Tarceva is usually used along with Gemzar. The most common side effects of Tarceva include an acne-like rash and diarrhea.

Clinical Trials

The National Cancer Institute notes that, among patients for whom currently-approved treatments may not extend life in a meaningful way, participating in a clinical trial could be a viable option.

There are a number of clinical trials in progress for pancreatic cancer testing various combinations of the above treatments, as well as newer treatments such as immunotherapy. While some of the treatments are just beginning to be studied with pancreatic cancer, they have sometimes led to dramatic control of advanced cancers, such as lung cancer, and bring hope that better treatments for pancreatic cancer will be available in the future.

Complementary Medicine (CAM)

At the current time, there are no alternative treatments that show any effectiveness in treating pancreatic cancer. Some alternative treatments, however, may help people cope with the symptoms caused by cancer and cancer treatments, and many of the larger cancer centers now offer integrative options. Examples include acupuncture, meditation, massage therapy, and yoga.


Many people seek out dietary and herbal supplements when they learn about the prognosis of pancreatic cancer.

It's important to note that some vitamin and nutritional supplements may decrease the effectiveness of cancer treatments

Research in the lab has looked at a few remedies used in Ayurveda, such as triphala, and nigella sativa (black caraway). While there have been promising findings showing an inhibition of the growth of human pancreatic cells grown in a test tube, we don't know if these compounds would have any effect on humans themselves. In addition, these supplements are largely unregulated in the United States and could possibly interfere with other treatments. This is a good reminder, however, to talk to your oncologist about any vitamins, minerals, or dietary supplements you are/are thinking about taking.

Interestingly, research looking at cancer cachexia (the syndrome of weight loss, loss of appetite, and loss of muscle mass that affects the majority of people with pancreatic cancer) has found that omega-3 fatty acids may be helpful—important, as there is very little that truly makes a difference in this syndrome. Since cachexia is thought to be the direct cause of death in 20% of people with cancer, this is worth talking to your oncologist about. There are many sources of dietary omega-3s, and most of the time oncologists recommend getting nutrients through diet rather than supplements. 

Palliative Care

Palliative care is not the same as hospice, and can actually be used even for people with highly curable tumors. It focuses on the health and wellbeing of a person living with cancer, rather than the treatment of cancer itself. Palliative care is actually the mainstay of treatment for the majority of people who are diagnosed with pancreatic cancer. This may include surgery or chemotherapy, as noted above, but also other options.

Examples include optimal pain management; control of other physical symptoms, such as digestive issues; nutritional support; and emotional support for stress, anxiety, and depression. Palliative care can also be helpful in addressing spiritual concerns, caregiver needs and communication, and practical issues ranging from insurance to financial and legal support.

Many cancer centers now offer consults with a palliative care team to make sure symptoms are addressed as well as possible. 

Home Remedies and Lifestyle

Since the quality of life with pancreatic cancer is of utmost importance, measures that improve it are paramount. Eating a healthy diet may not make a difference with your cancer, but most people feel better when they eat a diet rich in fruits and vegetables. Exercise is helpful and, perhaps counterintuitively, may help reduce cancer cachexia.

Some people wonder if it is worth it to quit smoking after being diagnosed, especially with advanced pancreatic cancer. The answer is yes. There are several strong reasons why quitting after a diagnosis of cancer can be very helpful. 

Was this page helpful?
Article Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. PDQ Adult Treatment Editorial Board. Pancreatic Cancer Treatment (PDQ®): Health Professional Version. 2019 Jul 15. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. Available from:

  2. Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat?Therap Adv Gastroenterol. 2013;6(4):321–337. doi:10.1177/1756283X13478680

  3. Enweluzo C, Aziz F. Pancreatic Cancer and Gastroenterology: A ReviewGastroenterology Res. 2013;6(3):81–84. doi:10.4021/gr563w

  4. Muniraj T, Barve P. Laparoscopic staging and surgical treatment of pancreatic cancerN Am J Med Sci. 2013;5(1):1–9. doi:10.4103/1947-2714.106183

  5. AMAEnweluzo C, Aziz F. Pancreatic Cancer and Gastroenterology: A ReviewGastroenterology Res. 2013;6(3):81–84. doi:10.4021/gr563w

  6. Buanes TA. Role of surgery in pancreatic cancerWorld J Gastroenterol. 2017;23(21):3765–3770. doi:10.3748/wjg.v23.i21.3765

  7. Karim SAM, Abdulla KS, Abdulkarim QH, Rahim FH. The outcomes and complications of pancreaticoduodenectomy (Whipple procedure): Cross sectional study. Int J Surg. 2018;52:383-387.

  8. Diener MK, Fitzmaurice C, Schwarzer G, et al. Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinomaCochrane Database Syst Rev. 2014;11(11):CD006053. Published 2014 Nov 11. doi:10.1002/14651858.CD006053.pub5

  9. Cečka F, Jon B, Subrt Z, Ferko A. Surgical technique in distal pancreatectomy: a systematic review of randomized trialsBiomed Res Int. 2014;2014:482906. doi:10.1155/2014/482906

  10. Heidt DG, Burant C, Simeone DM. Total pancreatectomy: indications, operative technique, and postoperative sequelae. J Gastrointest Surg. 2007;11(2):209-16.

  11. Chan HK, Ismail S. Side effects of chemotherapy among cancer patients in a Malaysian General Hospital: experiences, perceptions and informational needs from clinical pharmacists. Asian Pac J Cancer Prev. 2014;15(13):5305-9.

  12. Ho CK, Kleeff J, Friess H, Büchler MW. Complications of pancreatic surgeryHPB (Oxford). 2005;7(2):99–108. doi:10.1080/13651820510028936

  13. Buanes TA. Role of surgery in pancreatic cancerWorld J Gastroenterol. 2017;23(21):3765–3770. doi:10.3748/wjg.v23.i21.3765

  14. McEvoy SH, Lavelle LP, Hoare SM, et al. Pancreaticoduodenectomy: expected post-operative anatomy and complicationsBr J Radiol. 2014;87(1041):20140050. doi:10.1259/bjr.20140050

  15. Heidt DG, Burant C, Simeone DM. Total pancreatectomy: indications, operative technique, and postoperative sequelae. J Gastrointest Surg. 2007;11(2):209-16.

  16. Vujasinovic M, Valente R, Del Chiaro M, Permert J, Löhr JM. Pancreatic Exocrine Insufficiency in Pancreatic CancerNutrients. 2017;9(3):183. Published 2017 Feb 23. doi:10.3390/nu9030183

  17. Perinel J, Adham M. Palliative therapy in pancreatic cancer-palliative surgeryTransl Gastroenterol Hepatol. 2019;4:28. Published 2019 May 7. doi:10.21037/tgh.2019.04.03

  18. David JM, Kim S, Placencio-Hickok VR, Torosian A, Hendifar A, Tuli R. Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centersAdv Radiat Oncol. 2018;4(2):302–313. Published 2018 Nov 9. doi:10.1016/j.adro.2018.10.006

  19. Klaiber U, Leonhardt CS, Strobel O, Tjaden C, Hackert T, Neoptolemos JP. Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. Langenbecks Arch Surg. 2018;403(8):917-932.

  20. Seufferlein T, Ettrich TJ. Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC). Transl Gastroenterol Hepatol. 2019;4:21. Published 2019 Mar 27. doi:10.21037/tgh.2019.03.05

  21. Conroy T, Ducreux M. Adjuvant treatment of pancreatic cancer. Curr Opin Oncol. 2019;31(4):346-353.

  22. Berger AK, Haag GM, Ehmann M, Byl A, Jäger D, Springfeld C. Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patientBMC Gastroenterol. 2017;17(1):143. Published 2017 Dec 6. doi:10.1186/s12876-017-0709-3

  23. Molins EAG, Jusko WJ. Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells. AAPS J. 2018;20(5):80.

  24. Nurgali K, Jagoe RT, Abalo R. Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?Front Pharmacol. 2018;9:245. Published 2018 Mar 22. doi:10.3389/fphar.2018.00245

  25. Amanam I, Chung V. Targeted Therapies for Pancreatic CancerCancers (Basel). 2018;10(2):36. Published 2018 Jan 29. doi:10.3390/cancers10020036

  26. Kelley RK, Ko AH. Erlotinib in the treatment of advanced pancreatic cancerBiologics. 2008;2(1):83–95.

  27. Boeck S, Hausmann A, Reibke R, Schulz C, Heinemann V. Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anticancer Drugs. 2007;18(9):1109-11.

  28. Hall BR, Cannon A, Atri P, et al. Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. Oncotarget. 2018;9(27):19396-19405.

  29. Yue Q, Gao G, Zou G, Yu H, Zheng X. Natural Products as Adjunctive Treatment for Pancreatic Cancer: Recent Trends and AdvancementsBiomed Res Int. 2017;2017:8412508. doi:10.1155/2017/8412508

  30. Liu Y, Wang X, Sun X, Lu S, Liu S. Vitamin intake and pancreatic cancer risk reduction: A meta-analysis of observational studies. Medicine (Baltimore). 2018;97(13):e0114. doi:10.1097/MD.0000000000010114

  31. Banerjee S, Azmi AS, Padhye S, et al. Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer. Pharm Res. 2010;27(6):1146-58.

  32. Ding Y, Mullapudi B, Torres C, et al. Omega-3 Fatty Acids Prevent Early Pancreatic Carcinogenesis via Repression of the AKT PathwayNutrients. 2018;10(9):1289. Published 2018 Sep 12. doi:10.3390/nu10091289

  33. Perinel J, Adham M. Palliative therapy in pancreatic cancer-palliative surgeryTransl Gastroenterol Hepatol. 2019;4:28. Published 2019 May 7. doi:10.21037/tgh.2019.04.03

  34. Crippa S, Domínguez I, Rodríguez JR, et al. Quality of life in pancreatic cancer: analysis by stage and treatmentJ Gastrointest Surg. 2008;12(5):783–794. doi:10.1007/s11605-007-0391-9

Additional Reading